HERTFORDSHIRE, England and
PITTSBURGH, June 2, 2016 /PRNewswire/ -- Mylan N.V.
(NASDAQ, TASE: MYL) today announced the U.S. launch of Azacitidine
for Injection, 100 mg/vial, which is a generic version of Celgene's
Vidaza® Injection, 100 mg/vial. Mylan received final approval from
the U.S. Food and Drug Administration (FDA) for its Abbreviated New
Drug Application (ANDA) for this product. Azacitidine for Injection
is a nucleoside metabolic inhibitor indicated for the treatment of
the five French-American-British (FAB) subtypes of myelodysplastic
syndrome, a blood cell disorder that can occur as a result of
cancer treatments or can progress to leukemia.
Azacitidine for Injection, 100 mg/vial, had U.S. sales of
approximately $236.3 million for the
12 months ending March 31, 2016,
according to IMS Health.
Mylan's launch of this product adds to the company's portfolio
of more than 150 injectable products available to patients in the
U.S. across a broad array of therapeutic categories. Azacitidine
for Injection is also a part of a growing U.S. portfolio of more
than 20 oncology medications that includes treatments for breast,
lung, colorectal, ovarian and hematologic cancers.
Currently, Mylan has 254 ANDAs pending FDA approval representing
$108.3 billion in annual brand sales,
according to IMS Health. Forty-three of these pending ANDAs are
potential first-to-file opportunities, representing $37.2 billion in annual brand sales, for the 12
months ending December 31, 2015,
according to IMS Health.
This press release includes statements that constitute
"forward-looking statements," including with regard to the
statement that Mylan's launch of this product adds to the company's
growing portfolio of more than 150 injectable products available to
patients in the U.S. across a broad array of therapeutic categories
and is part of a growing U.S. portfolio of more than 20 oncology
medications. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Because such statements inherently involve risks and uncertainties,
actual future results may differ materially from those expressed or
implied by such forward-looking statements. Factors that could
cause or contribute to such differences include, but are not
limited to: any changes in or difficulties with Mylan's ability to
develop, manufacture, and commercialize products; the impact of
competition and the use of legal, regulatory and legislative
strategies by competitors or other third parties to delay or
prevent our introduction of new products; changes in economic and
financial conditions; changes in third party relationships; actions
and decisions of healthcare and pharmaceutical regulators, and
changes in healthcare and pharmaceutical laws and regulations, in
the United States and abroad;
other uncertainties and matters beyond the control of management;
and the other risks detailed in Mylan's filings with the Securities
and Exchange Commission. Mylan undertakes no obligation to update
these statements for revisions or changes after the date of this
release.
Mylan is a global pharmaceutical company committed to setting
new standards in healthcare. Working together around the world to
provide 7 billion people access to high quality medicine, we
innovate to satisfy unmet needs; make reliability and service
excellence a habit; do what's right, not what's easy; and impact
the future through passionate global leadership. We offer a growing
portfolio of more than 1,400 generic and branded pharmaceuticals,
including antiretroviral therapies on which approximately 50% of
people being treated for HIV/AIDS in the developing world depend.
We market our products in approximately 165 countries and
territories. Our global R&D and manufacturing platform includes
more than 50 facilities, and we are one of the world's largest
producers of active pharmaceutical ingredients. Every member of our
nearly 35,000-strong workforce is dedicated to creating better
health for a better world, one person at a time. Learn more at
mylan.com.
Logo - http://photos.prnewswire.com/prnh/20140423/77793
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mylan-launches-generic-vidaza-injection-300278047.html
SOURCE Mylan N.V.